Thalidomide (Thalomid)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 06:41, 13 May 2012 by Dryang (talk | contribs) (Text replace - "or the prescribing information<ref name="insert"></ref>." to "or the prescribing information.<ref name="insert"></ref>")
Jump to navigation Jump to search

General information

Class/mechanism: Immunomodulatory drug (IMiD); mechanism not fully understood.

Thalidomide's mechanism may involve immunomodulatory, antiinflammatory, and antiangiogenic effects and suppression of tumor necrosis factor-alpha (TNF-α) from peripheral blood mononuclear cells. Thalidomide has been observed to inhibit angiogenesis in a human umbilical artery explant model in vitro.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information

References

  1. ↑ 1.0 1.1 1.2 Thalidomide (Thalomid) package insert
  2. ↑ Thalidomide (Thalomid) package insert (locally hosted backup)
  3. ↑ Thalomid manufacturer's website
  4. ↑ S.T.E.P.S. System for Thalidomide Education and Prescribing Safety
  5. ↑ Thalidomide (Thalomid) patient drug information (Chemocare)
  6. ↑ Thalidomide (Thalomid) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Thalidomide_(Thalomid)&oldid=1507"